Who Paid My Doc Search
Menu
Organisation paid for research Program year 2023 Source: CMS Open Payments

Bergstrom Eye Research LLC

Neither a doctor nor a teaching hospital

Research payments

$355,161

83 payments

Through program year 2023, Bergstrom Eye Research LLC is reported as receiving $355,161 in research payments, across 83 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $14,365 1
2022 Research $106,267 5
2021 Research $14,432 3
2020 Research $26,167 43
2019 Research $193,929 31

Breakdown

Who paid Research payments · program years 2019–2023
  1. Allergan Inc. $183,976 61 payments
  2. Novartis Pharmaceuticals Corporation $85,712 2 payments
  3. AbbVie, Inc. $34,978 5 payments
  4. Bausch Health US, LLC $30,689 6 payments
  5. Sun Pharmaceutical Industries Inc. $19,805 9 payments
Studies the money was for Research payments · program years 2019–2023
  1. A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension $161,397 26 payments
  2. A 12-Week Parallel Group, Randomized, Placebo-Controlled, Double-Blinded, Multi-Center Study to Evaluate Efficacy and Safety of 2 Concentrations of Saf312 Eye Drops (5 MG/ML and 15 MG/ML) Used Twice-Daily in the Treatment of Post-Operative Corneal Induced $85,654 1 payment
  3. Long-term Safety and Efficacy Extension Trial of Bimatoprost SR $34,978 5 payments
  4. A Prospective, Post Approval Study to Evaluate the Trulign Toric Posterior Chamber Intraocular Lens Iol $30,689 6 payments
  5. A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (0.1% Dexamethasone) Compared to Vehicle in the Treatment of Subjects With Blepharitis $19,805 9 payments
  6. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $14,365 1 payment
  7. Efficacy and Safety of Bimatoprost Sustained-Release Sr in Patients With Open-Angle Glaucoma Or Ocular Hypertension $3,132 8 payments
  8. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patient with Open Angle Glaucoma or Ocular Hypertension $1,840 6 payments
  9. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $1,809 15 payments
  10. Efficacy and Safety of Bimatoprost Sustained-Release (Sr) in Patients With Open-Angle Glaucoma Or Ocular Hypertension $1,425 4 payments
What the money was spent on Research payments · program years 2019–2023
  1. Other $19,805 9 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record